GlassScriptPhysician profile
Michael Schloss
NPI 1154959203
$2,467.98
in general payments reported to CMS, 2019-2025
13 companies · $2,044 in 2025
The $2,044 reported for 2025 was more than what 86% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $424 · 2025: $2,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,226 · Travel and Lodging: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,226.05 |
| Travel and Lodging | $241.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,575.25 | 2025 | Proclaim, Durata, Eterna |
| Medtronic, INC. | $379.53 | 2024 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Mml US, INC. | $208.49 | 2025 | Reactiv8 |
| Boston Scientific Corporation | $54.02 | 2025 | Intracept |
| Novo Nordisk INC | $41.60 | 2024-2025 | Wegovy |
| Saluda Medical Americas, INC. | $37.19 | 2025 | Evoke |
| Nalu Medical, INC. | $35.17 | 2025 | Nalu Neurostimulation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.15 | 2025 | Relistor |
| Abbvie INC. | $29.12 | 2025 | |
| Averitas Pharma INC. | $26.74 | 2025 | Qutenza |
| Pacira Pharmaceuticals Incorporated | $22.03 | 2024 | Iovera |
| Spr Therapeutics, INC | $16.03 | 2025 | Sprint Pns System |
| Globus Medical, INC. | $13.66 | 2025 | Vyrsa V1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schloss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.